Journal
CHEMISTRY-A EUROPEAN JOURNAL
Volume 26, Issue 5, Pages 1127-1135Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/chem.201904586
Keywords
bismuth; imaging agents; luminescence; nanoparticles; theranostics
Categories
Funding
- National Natural Science Foundation of China [21771175, 21701166, 51472236]
- National Basic Research Program of China (973 Program) [2014CB643803]
- Natural Science Foundation of Jilin province [20170101145JC, 20190201235JC]
- Key Program of the Frontier Science of the Chinese Academy of Sciences [YZDY-SSW-460 JSC018]
Ask authors/readers for more resources
Non-invasive theranostics that integrate the advantages of multimodality imaging and therapeutics have great potential in the field of biomedicine. Herein, a new nanohybrid based on Bi2Se3-conjugated upconversion nanoparticles (UCNPs) has been successfully developed through a simple in situ growth strategy. Under 808 nm near-infrared laser irradiation, the UCNPs can emit bright visible light, whereas the Bi2Se3 nanomaterial exhibits efficient photothermal conversion capacity. Moreover, the as-synthesized UCNP-Bi2Se3 nanohybrid exhibits efficient cell upconversion luminescence (UCL), reasonable CT imaging, and admirable cancer cell ablation capacity, further emphasizing the efficiency of this strategy for simultaneous UCL imaging and photothermal therapy. The designed theranostic strategy guided by dual-modal imaging endowed with real-time dynamic monitoring, remote controllability, and non-invasiveness makes the UCNP-Bi2Se3 nanohybrid an ideal candidate for non-invasive multimodal imaging-guided photothermal therapy for the precise diagnosis and treatment of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available